CN109609650B - 用于诊断和治疗肝细胞癌的生物标志物 - Google Patents
用于诊断和治疗肝细胞癌的生物标志物 Download PDFInfo
- Publication number
- CN109609650B CN109609650B CN201910097674.0A CN201910097674A CN109609650B CN 109609650 B CN109609650 B CN 109609650B CN 201910097674 A CN201910097674 A CN 201910097674A CN 109609650 B CN109609650 B CN 109609650B
- Authority
- CN
- China
- Prior art keywords
- hepatocellular carcinoma
- gene
- primer
- kit
- specifically
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 206010073071 hepatocellular carcinoma Diseases 0.000 title claims abstract description 34
- 231100000844 hepatocellular carcinoma Toxicity 0.000 title claims abstract description 33
- 239000000090 biomarker Substances 0.000 title abstract description 11
- 238000011282 treatment Methods 0.000 title description 8
- 238000003745 diagnosis Methods 0.000 title description 6
- 239000003153 chemical reaction reagent Substances 0.000 claims abstract description 8
- 230000014509 gene expression Effects 0.000 claims description 24
- 239000000523 sample Substances 0.000 claims description 22
- 150000007523 nucleic acids Chemical class 0.000 claims description 15
- 102000039446 nucleic acids Human genes 0.000 claims description 14
- 108020004707 nucleic acids Proteins 0.000 claims description 14
- 108020005187 Oligonucleotide Probes Proteins 0.000 claims description 11
- 239000002751 oligonucleotide probe Substances 0.000 claims description 11
- 230000003321 amplification Effects 0.000 claims description 10
- 238000003199 nucleic acid amplification method Methods 0.000 claims description 10
- 239000012528 membrane Substances 0.000 claims description 9
- 238000012165 high-throughput sequencing Methods 0.000 claims description 7
- 238000004364 calculation method Methods 0.000 claims description 5
- 239000003795 chemical substances by application Substances 0.000 claims description 5
- 238000011529 RT qPCR Methods 0.000 claims description 2
- 238000007901 in situ hybridization Methods 0.000 claims description 2
- 238000003757 reverse transcription PCR Methods 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract description 10
- 210000005229 liver cell Anatomy 0.000 abstract description 2
- 210000001519 tissue Anatomy 0.000 description 24
- 108090000623 proteins and genes Proteins 0.000 description 23
- 206010028980 Neoplasm Diseases 0.000 description 20
- 108020005198 Long Noncoding RNA Proteins 0.000 description 18
- 239000002299 complementary DNA Substances 0.000 description 18
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 14
- 208000014018 liver neoplasm Diseases 0.000 description 12
- 238000000034 method Methods 0.000 description 12
- 101150084750 1 gene Proteins 0.000 description 11
- 108020004414 DNA Proteins 0.000 description 11
- 201000011510 cancer Diseases 0.000 description 11
- 239000003112 inhibitor Substances 0.000 description 11
- 201000007270 liver cancer Diseases 0.000 description 11
- 239000000047 product Substances 0.000 description 7
- 108091046869 Telomeric non-coding RNA Proteins 0.000 description 6
- 230000000295 complement effect Effects 0.000 description 6
- 238000001514 detection method Methods 0.000 description 6
- 108020004999 messenger RNA Proteins 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- 102000040430 polynucleotide Human genes 0.000 description 6
- 108091033319 polynucleotide Proteins 0.000 description 6
- 239000002157 polynucleotide Substances 0.000 description 6
- 238000012163 sequencing technique Methods 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 230000000692 anti-sense effect Effects 0.000 description 5
- 239000002246 antineoplastic agent Substances 0.000 description 5
- 239000003550 marker Substances 0.000 description 5
- 238000004393 prognosis Methods 0.000 description 5
- 238000012216 screening Methods 0.000 description 5
- 239000000758 substrate Substances 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 4
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- 230000002159 abnormal effect Effects 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 238000004090 dissolution Methods 0.000 description 4
- 239000002244 precipitate Substances 0.000 description 4
- 230000001105 regulatory effect Effects 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 108700011259 MicroRNAs Proteins 0.000 description 3
- 108020004459 Small interfering RNA Proteins 0.000 description 3
- 239000011324 bead Substances 0.000 description 3
- 239000012634 fragment Substances 0.000 description 3
- 238000010438 heat treatment Methods 0.000 description 3
- 238000009396 hybridization Methods 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 239000002679 microRNA Substances 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 239000002773 nucleotide Substances 0.000 description 3
- 125000003729 nucleotide group Chemical group 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 238000010839 reverse transcription Methods 0.000 description 3
- 230000002441 reversible effect Effects 0.000 description 3
- 239000004055 small Interfering RNA Substances 0.000 description 3
- 239000007790 solid phase Substances 0.000 description 3
- 238000001356 surgical procedure Methods 0.000 description 3
- 231100000588 tumorigenic Toxicity 0.000 description 3
- 230000000381 tumorigenic effect Effects 0.000 description 3
- 230000003612 virological effect Effects 0.000 description 3
- MLDQJTXFUGDVEO-UHFFFAOYSA-N BAY-43-9006 Chemical compound C1=NC(C(=O)NC)=CC(OC=2C=CC(NC(=O)NC=3C=C(C(Cl)=CC=3)C(F)(F)F)=CC=2)=C1 MLDQJTXFUGDVEO-UHFFFAOYSA-N 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 108091093094 Glycol nucleic acid Proteins 0.000 description 2
- 241000711549 Hepacivirus C Species 0.000 description 2
- 241000282414 Homo sapiens Species 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 239000005511 L01XE05 - Sorafenib Substances 0.000 description 2
- 206010027476 Metastases Diseases 0.000 description 2
- 239000004743 Polypropylene Substances 0.000 description 2
- 238000012228 RNA interference-mediated gene silencing Methods 0.000 description 2
- 102000006382 Ribonucleases Human genes 0.000 description 2
- 108010083644 Ribonucleases Proteins 0.000 description 2
- 108091046915 Threose nucleic acid Proteins 0.000 description 2
- 102000004243 Tubulin Human genes 0.000 description 2
- 108090000704 Tubulin Proteins 0.000 description 2
- 102100037111 Uracil-DNA glycosylase Human genes 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 231100000504 carcinogenesis Toxicity 0.000 description 2
- 229940044683 chemotherapy drug Drugs 0.000 description 2
- 238000013211 curve analysis Methods 0.000 description 2
- 229940127089 cytotoxic agent Drugs 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 238000013399 early diagnosis Methods 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 230000009368 gene silencing by RNA Effects 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 239000002502 liposome Substances 0.000 description 2
- 230000036210 malignancy Effects 0.000 description 2
- 230000009401 metastasis Effects 0.000 description 2
- 238000002493 microarray Methods 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 108091027963 non-coding RNA Proteins 0.000 description 2
- 102000042567 non-coding RNA Human genes 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- -1 polypropylene Polymers 0.000 description 2
- 229920001155 polypropylene Polymers 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 229960003787 sorafenib Drugs 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 238000013518 transcription Methods 0.000 description 2
- 230000035897 transcription Effects 0.000 description 2
- 238000002054 transplantation Methods 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- OTLLEIBWKHEHGU-UHFFFAOYSA-N 2-[5-[[5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy]-3,4-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3,5-dihydroxy-4-phosphonooxyhexanedioic acid Chemical compound C1=NC=2C(N)=NC=NC=2N1C(C(C1O)O)OC1COC1C(CO)OC(OC(C(O)C(OP(O)(O)=O)C(O)C(O)=O)C(O)=O)C(O)C1O OTLLEIBWKHEHGU-UHFFFAOYSA-N 0.000 description 1
- 229930195730 Aflatoxin Natural products 0.000 description 1
- 231100000699 Bacterial toxin Toxicity 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 102000011727 Caspases Human genes 0.000 description 1
- 108010076667 Caspases Proteins 0.000 description 1
- 108010077544 Chromatin Proteins 0.000 description 1
- 206010009208 Cirrhosis alcoholic Diseases 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- 102000016736 Cyclin Human genes 0.000 description 1
- 108050006400 Cyclin Proteins 0.000 description 1
- 239000012624 DNA alkylating agent Substances 0.000 description 1
- 101150112014 Gapdh gene Proteins 0.000 description 1
- 206010064571 Gene mutation Diseases 0.000 description 1
- 241000700721 Hepatitis B virus Species 0.000 description 1
- 102100034343 Integrase Human genes 0.000 description 1
- 108090001030 Lipoproteins Proteins 0.000 description 1
- 102000004895 Lipoproteins Human genes 0.000 description 1
- 108091007460 Long intergenic noncoding RNA Proteins 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 101710163270 Nuclease Proteins 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 102000011931 Nucleoproteins Human genes 0.000 description 1
- 108010061100 Nucleoproteins Proteins 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 239000004952 Polyamide Substances 0.000 description 1
- 238000002123 RNA extraction Methods 0.000 description 1
- 239000013614 RNA sample Substances 0.000 description 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 230000007488 abnormal function Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 239000005409 aflatoxin Substances 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 208000010002 alcoholic liver cirrhosis Diseases 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000000137 annealing Methods 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 239000002256 antimetabolite Substances 0.000 description 1
- 239000003972 antineoplastic antibiotic Substances 0.000 description 1
- 229940045988 antineoplastic drug protein kinase inhibitors Drugs 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 239000000688 bacterial toxin Substances 0.000 description 1
- 238000004166 bioassay Methods 0.000 description 1
- 229920000249 biocompatible polymer Polymers 0.000 description 1
- 238000003766 bioinformatics method Methods 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 230000005773 cancer-related death Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 239000000919 ceramic Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 210000003483 chromatin Anatomy 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000000875 corresponding effect Effects 0.000 description 1
- 239000013601 cosmid vector Substances 0.000 description 1
- 229940043378 cyclin-dependent kinase inhibitor Drugs 0.000 description 1
- NHVNXKFIZYSCEB-XLPZGREQSA-N dTTP Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)C1 NHVNXKFIZYSCEB-XLPZGREQSA-N 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 230000000368 destabilizing effect Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 239000012470 diluted sample Substances 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000003534 dna topoisomerase inhibitor Substances 0.000 description 1
- 230000019975 dosage compensation by inactivation of X chromosome Effects 0.000 description 1
- 230000002222 downregulating effect Effects 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 239000002158 endotoxin Substances 0.000 description 1
- 238000001976 enzyme digestion Methods 0.000 description 1
- 230000006718 epigenetic regulation Effects 0.000 description 1
- 239000002095 exotoxin Substances 0.000 description 1
- 231100000776 exotoxin Toxicity 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 239000003667 hormone antagonist Substances 0.000 description 1
- 230000003100 immobilizing effect Effects 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 238000012296 in situ hybridization assay Methods 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 229920006008 lipopolysaccharide Polymers 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 238000012067 mathematical method Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 238000011880 melting curve analysis Methods 0.000 description 1
- 210000004779 membrane envelope Anatomy 0.000 description 1
- 230000006371 metabolic abnormality Effects 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 229910021645 metal ion Inorganic materials 0.000 description 1
- 239000003475 metalloproteinase inhibitor Substances 0.000 description 1
- 239000002991 molded plastic Substances 0.000 description 1
- 230000009456 molecular mechanism Effects 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- 229920005615 natural polymer Polymers 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 230000001613 neoplastic effect Effects 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 108091008104 nucleic acid aptamers Proteins 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 229920006284 nylon film Polymers 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 239000013600 plasmid vector Substances 0.000 description 1
- 229920002647 polyamide Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000004952 protein activity Effects 0.000 description 1
- 239000003909 protein kinase inhibitor Substances 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 238000003753 real-time PCR Methods 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000022532 regulation of transcription, DNA-dependent Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 108020004418 ribosomal RNA Proteins 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 229920001059 synthetic polymer Polymers 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 238000002626 targeted therapy Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 229940044693 topoisomerase inhibitor Drugs 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- 230000005748 tumor development Effects 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 241000701447 unidentified baculovirus Species 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 238000010200 validation analysis Methods 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/178—Oligonucleotides characterized by their use miRNA, siRNA or ncRNA
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Hospice & Palliative Care (AREA)
- Biophysics (AREA)
- Oncology (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
Description
Claims (7)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201910097674.0A CN109609650B (zh) | 2019-01-31 | 2019-01-31 | 用于诊断和治疗肝细胞癌的生物标志物 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201910097674.0A CN109609650B (zh) | 2019-01-31 | 2019-01-31 | 用于诊断和治疗肝细胞癌的生物标志物 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN109609650A CN109609650A (zh) | 2019-04-12 |
CN109609650B true CN109609650B (zh) | 2021-09-28 |
Family
ID=66021699
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201910097674.0A Active CN109609650B (zh) | 2019-01-31 | 2019-01-31 | 用于诊断和治疗肝细胞癌的生物标志物 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN109609650B (zh) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111808952B (zh) * | 2020-06-08 | 2023-03-28 | 山东第一医科大学(山东省医学科学院) | 一种肿瘤lncRNA标志物及其应用 |
CN111808953B (zh) * | 2020-06-08 | 2022-11-04 | 山东第一医科大学第二附属医院 | 一种用于肿瘤诊断和治疗的lncRNA标志物 |
CN112535734A (zh) * | 2021-01-15 | 2021-03-23 | 辽宁省肿瘤医院 | 一种抑制LncRNA-RP5表达的试剂在制备治疗小细胞肺癌药物中的用途 |
CN114875156A (zh) * | 2022-06-29 | 2022-08-09 | 南通大学附属医院 | Mogat2在制备肝细胞癌诊断和预后判断产品中的应用 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108707672A (zh) * | 2018-06-13 | 2018-10-26 | 北京泱深生物信息技术有限公司 | Duxap8在肝细胞癌诊断和治疗中的应用 |
-
2019
- 2019-01-31 CN CN201910097674.0A patent/CN109609650B/zh active Active
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108707672A (zh) * | 2018-06-13 | 2018-10-26 | 北京泱深生物信息技术有限公司 | Duxap8在肝细胞癌诊断和治疗中的应用 |
Non-Patent Citations (1)
Title |
---|
Systematic analysis reveals a lncRNA-mRNA co-expression network associated with platinum resistance in high-grade serous ovarian cancer;Lei Fanget,al.;《Invest New Drugs.》;20171030;第36卷(第2期);摘要 * |
Also Published As
Publication number | Publication date |
---|---|
CN109609650A (zh) | 2019-04-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN109609650B (zh) | 用于诊断和治疗肝细胞癌的生物标志物 | |
CN107881241B (zh) | 基因标志物在乳腺癌诊断和治疗中的应用 | |
JP2010510769A (ja) | 食道癌の診断ならびに患者の生存の予後および改善のための方法および組成物 | |
KR20100084619A (ko) | 마이크로―RNA/miRNA 의 감별 검출을 이용한 특정 암에 대한 진단 및 예후 | |
CN109609648B (zh) | 与肝癌相关的lncRNA标志物及其检测引物和应用 | |
CN109182521B (zh) | circRNA作为甲状腺乳头状癌标志物的应用 | |
CN110714080B (zh) | 用于诊断和治疗乳腺癌的生物标志物 | |
WO2014152355A2 (en) | Osteosarcoma-associated risk markers and uses thereof | |
CN110628913B (zh) | 一种与乳腺癌相关的lncRNA标志物 | |
CN108949969B (zh) | 长链非编码rna在结直肠癌中的应用 | |
EP3390661B1 (en) | Use of antisense long non-coding rnas for the diagnosis of prostate cancer | |
WO2009140670A2 (en) | Methods for assessing colorectal cancer and compositions for use therein | |
CN108085389B (zh) | 一种与乳腺癌相关的lncRNA及其应用 | |
CN110628914B (zh) | 与乳腺癌相关的lncRNA标志物及其检测引物和应用 | |
CN108707672B (zh) | Duxap8在肝细胞癌诊断和治疗中的应用 | |
CN105985955B (zh) | 小rna组成的指纹图谱在胃癌中的应用 | |
US20180113133A1 (en) | Gene relevant to papillary thyroid tumors | |
CN110055333B (zh) | Rp11-116o18.1作为分子标志物在肺癌中的应用 | |
CN109913552B (zh) | 一种食管鳞癌诊疗靶点及应用 | |
Lee et al. | MicroRNA-23a: a novel serum based diagnostic biomarker for lung adenocarcinoma | |
CN107937550B (zh) | 一种与乳腺癌发生发展相关的生物标志物及其应用 | |
CN111440867B (zh) | 生物标志物在肝癌诊断和治疗中的应用 | |
WO2016160882A1 (en) | Methods for diagnosing and treating colorectal cancer using mirna549a | |
EP2622097B1 (en) | Prognostic methods, compositions and kits for prediction of acute lymphoblastic leukemia (all) relapse | |
WO2010070637A2 (en) | Method for distinguishing between adrenal tumors |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20240306 Address after: No. 6699, Qingdao Road, Huaiyin District, Jinan City, Shandong Province Patentee after: Shandong First Medical University (Shandong Academy of Medical Sciences) Country or region after: China Patentee after: The Second Affiliated Hospital of Shandong First Medical University Address before: 271016 School of Radiology, Taishan Medical College, Changcheng Road, Tai'an City, Shandong Province Patentee before: TAISHAN MEDICAL University Country or region before: China Patentee before: AFFILIATED HOSPITAL OF TAISHAN MEDICAL University |
|
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20240401 Address after: C416, Building 1, Overseas Students Pioneer Park, No. 69 Huayang Road, Lixia District, Jinan, Shandong 250000 Patentee after: Shandong Kaige Intelligent Machine Co.,Ltd. Country or region after: China Address before: No. 6699, Qingdao Road, Huaiyin District, Jinan City, Shandong Province Patentee before: Shandong First Medical University (Shandong Academy of Medical Sciences) Country or region before: China Patentee before: The Second Affiliated Hospital of Shandong First Medical University |